FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378674773> ?p ?o ?g. }

• W4378674773 abstract "Cardiovascular disease is a leading cause of death in chronic kidney disease (CKD), yet the mechanisms remain unclear. Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) are endogenous nitric oxide synthase inhibitors shown to be independent risk markers for cardiovascular disease. Previous research has predominantly focused on ADMA as a primary risk marker of reduced vascular function and increased cardiovascular mortality in end-stage (stage 5) CKD. However, limited research has explored the potential roles of ADMA and SDMA in relation to vascular function in the middle stages (stages 3 and 4) of CKD. Therefore, we tested the hypothesis that patients with stage 3-4 CKD would have elevated circulating ADMA and SDMA, which would correspond to a reduced vascular function compared to controls. We studied 17 patients with stage 3-4 CKD (age: 66 ± 7 years, 5 males, eGFR: 44 ± 16 ml/min/1.73m 2 ) and 8 controls (age: 59 ± 7 years; 3 males, eGFR: 81 ± 14 ml/min/1.73m 2 ). ADMA and SDMA were assessed in whole blood serum using liquid chromatography/tandem mass spectrometry by a commercial laboratory (Quest diagnostics). Macro- and micro-vascular function were assessed as brachial artery flow-mediated dilation (FMD; %) and peak reactive hyperemia blood velocity, respectively, using duplex Doppler ultrasound. Arterial stiffness was assessed as carotid-femoral pulse wave velocity (cfPWV) using arterial tonometry. Data are expressed as mean ± standard deviation. Interestingly, we found that SDMA (control: 103 ± 14, CKD: 143 ± 42 ng/mL, p=0.01) but not ADMA (control: 109 ± 7; CKD: 111 ± 28 ng/mL, p=0.40) was significantly elevated in patients with CKD compared to controls. FMD was significantly reduced in the CKD group (control: 5.04 ± 2.59.; CKD: 3.18 ± 1.98 %, p=0.03), while peak blood velocity was similar between groups (control: 53.47 ± 10.40, CKD: 59.72 ± 23.99 cm/s, p=0.25). There tended to be a negative relationship between SDMA concentrations and FMD (R= -0.31, p=0.07), whereas there was no relationship between ADMA and FMD (R= 0.22, p=0.14). Arterial stiffness was also significantly greater in the patient with CKD compared to controls (control: 6.74 ± 0.91, CKD: 7.95 ± 1.60 m/s, p=0.034). These data suggest that patients with stage 3-4 CKD who have elevated circulating SDMA but not ADMA exhibit an impaired macro-vascular function. Moreover, an augmented cfPWV also suggests increased arterial stiffness in patients with CKD with elevated SDMA. Collectively, these preliminary findings suggest that SDMA, but not ADMA, may play a more predominant role in mediating impaired vascular function in the middle stages of CKD. This project was supported by the National Heart, Lung, and Blood Institute R01 HL-127071. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process." @default.
• W4378674773 created "2023-05-30" @default.
• W4378674773 creator A5008381500 @default.
• W4378674773 creator A5014015932 @default.
• W4378674773 creator A5038351368 @default.
• W4378674773 creator A5049531358 @default.
• W4378674773 creator A5058714510 @default.
• W4378674773 creator A5062302009 @default.
• W4378674773 creator A5079396078 @default.
• W4378674773 creator A5085200806 @default.
• W4378674773 date "2023-05-01" @default.
• W4378674773 modified "2023-10-17" @default.
• W4378674773 title "Decreased peripheral vascular function in patients with stage 3 and 4 chronic kidney disease who have elevated symmetric dimethylarginine but not asymmetric dimethylarginine" @default.
• W4378674773 doi "https://doi.org/10.1152/physiol.2023.38.s1.5734348" @default.
• W4378674773 hasPublicationYear "2023" @default.
• W4378674773 type Work @default.
• W4378674773 citedByCount "0" @default.
• W4378674773 crossrefType "journal-article" @default.
• W4378674773 hasAuthorship W4378674773A5008381500 @default.
• W4378674773 hasAuthorship W4378674773A5014015932 @default.
• W4378674773 hasAuthorship W4378674773A5038351368 @default.
• W4378674773 hasAuthorship W4378674773A5049531358 @default.
• W4378674773 hasAuthorship W4378674773A5058714510 @default.
• W4378674773 hasAuthorship W4378674773A5062302009 @default.
• W4378674773 hasAuthorship W4378674773A5079396078 @default.
• W4378674773 hasAuthorship W4378674773A5085200806 @default.
• W4378674773 hasConcept C120770815 @default.
• W4378674773 hasConcept C126322002 @default.
• W4378674773 hasConcept C134018914 @default.
• W4378674773 hasConcept C159641895 @default.
• W4378674773 hasConcept C164705383 @default.
• W4378674773 hasConcept C2775850156 @default.
• W4378674773 hasConcept C2777468819 @default.
• W4378674773 hasConcept C2777604165 @default.
• W4378674773 hasConcept C2778319312 @default.
• W4378674773 hasConcept C2778653478 @default.
• W4378674773 hasConcept C2779877776 @default.
• W4378674773 hasConcept C3019128504 @default.
• W4378674773 hasConcept C515207424 @default.
• W4378674773 hasConcept C55493867 @default.
• W4378674773 hasConcept C71924100 @default.
• W4378674773 hasConcept C84393581 @default.
• W4378674773 hasConcept C86803240 @default.
• W4378674773 hasConceptScore W4378674773C120770815 @default.
• W4378674773 hasConceptScore W4378674773C126322002 @default.
• W4378674773 hasConceptScore W4378674773C134018914 @default.
• W4378674773 hasConceptScore W4378674773C159641895 @default.
• W4378674773 hasConceptScore W4378674773C164705383 @default.
• W4378674773 hasConceptScore W4378674773C2775850156 @default.
• W4378674773 hasConceptScore W4378674773C2777468819 @default.
• W4378674773 hasConceptScore W4378674773C2777604165 @default.
• W4378674773 hasConceptScore W4378674773C2778319312 @default.
• W4378674773 hasConceptScore W4378674773C2778653478 @default.
• W4378674773 hasConceptScore W4378674773C2779877776 @default.
• W4378674773 hasConceptScore W4378674773C3019128504 @default.
• W4378674773 hasConceptScore W4378674773C515207424 @default.
• W4378674773 hasConceptScore W4378674773C55493867 @default.
• W4378674773 hasConceptScore W4378674773C71924100 @default.
• W4378674773 hasConceptScore W4378674773C84393581 @default.
• W4378674773 hasConceptScore W4378674773C86803240 @default.
• W4378674773 hasIssue "S1" @default.
• W4378674773 hasLocation W43786747731 @default.
• W4378674773 hasOpenAccess W4378674773 @default.
• W4378674773 hasPrimaryLocation W43786747731 @default.
• W4378674773 hasRelatedWork W1185247290 @default.
• W4378674773 hasRelatedWork W2002269004 @default.
• W4378674773 hasRelatedWork W2019101031 @default.
• W4378674773 hasRelatedWork W2054129325 @default.
• W4378674773 hasRelatedWork W2074488913 @default.
• W4378674773 hasRelatedWork W2101974291 @default.
• W4378674773 hasRelatedWork W2126199931 @default.
• W4378674773 hasRelatedWork W2144543103 @default.
• W4378674773 hasRelatedWork W2790178323 @default.
• W4378674773 hasRelatedWork W84304806 @default.
• W4378674773 hasVolume "38" @default.
• W4378674773 isParatext "false" @default.
• W4378674773 isRetracted "false" @default.
• W4378674773 workType "article" @default.